Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Imiquimod
Drug ID BADD_D01142
Description Imiquimod is an immune response modifier that acts as a toll-like receptor 7 agonist. Imiquimod is commonly used topically to treat warts on the skin of the genital and anal areas. Imiquimod does not cure warts, and new warts may appear during treatment. Imiquimod does not fight the viruses that cause warts directly, however, it does help to relieve and control wart production. Miquimod is also used to treat a skin condition of the face and scalp called actinic keratoses and certain types of skin cancer called superficial basal cell carcinoma.
Indications and Usage For the topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adults. Also indicated for the treatment of external genital and perianal warts/condyloma acuminata in individuals 12 years old and above.
Marketing Status Prescription; Discontinued
ATC Code D06BB10
DrugBank ID DB00724
KEGG ID D02500
MeSH ID D000077271
PubChem ID 57469
TTD Drug ID D06CTE
NDC Product Code 22365-121; 51927-0168; 66039-829; 0395-8244; 0093-3133; 63629-8818; 64552-4008; 62147-0087; 51672-4145; 99207-270; 62350-0077; 99207-276; 68462-536; 62147-0072; 45802-368; 68682-272; 99207-260; 72189-084; 71052-160; 99207-271; 0168-0432; 51552-1538; 58175-0397; 11517-270; 72643-006; 11517-275; 51927-4898; 51672-4174; 11517-262
Synonyms Imiquimod | 1-Isobutyl-1H-imidazo(4,5-c)quinolin-4-amine | S 26308 | S-26308 | R 837 | R-837 | R837 | Zyclara | Aldara
Chemical Information
Molecular Formula C14H16N4
CAS Registry Number 99011-02-6
SMILES CC(C)CN1C=NC2=C1C3=CC=CC=C3N=C2N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dizziness02.01.02.004; 24.06.02.007; 17.02.05.0030.010427%
Drug hypersensitivity10.01.01.001--Not Available
Dry mouth07.06.01.002--
Dry skin23.03.03.001--
Dyspareunia19.08.05.004; 21.03.02.016--
Dyspepsia07.01.02.001--
Dyspnoea22.02.01.004; 02.01.03.002--
Dysuria20.02.02.002--
Ear disorder04.03.01.001--Not Available
Eczema23.03.04.006--
Erythema23.03.06.0010.020855%Not Available
Erythema multiforme23.03.01.003; 10.01.03.0150.015062%
Erythrodermic psoriasis23.03.14.0070.003476%Not Available
Eye disorder06.08.03.001--Not Available
Eye infection11.01.06.001; 06.04.05.007--
Eye irritation06.04.05.0030.005793%Not Available
Eye pain06.08.03.0020.005793%
Eyelid oedema23.04.01.003; 10.01.05.001; 06.04.04.0040.002317%Not Available
Face oedema23.04.01.004; 10.01.05.002; 08.01.07.003--
Facial pain08.01.08.0120.002317%
Fatigue08.01.01.0020.018538%
Febrile convulsion08.05.02.009; 17.12.03.004--Not Available
Feeling abnormal08.01.09.014--Not Available
Feeling hot08.01.09.009--Not Available
Flushing24.03.01.002; 23.06.05.003; 08.01.03.025--
Folliculitis23.09.04.007; 11.01.12.018--
Fungal infection11.03.05.001--Not Available
Gait disturbance17.02.05.016; 08.01.02.0020.004634%
Gastrooesophageal reflux disease07.02.02.003--
Gastrointestinal disorder07.11.01.001--Not Available
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 12 Pages